Comprehensive Study Reveals 94.5% Survival Rate for Childhood Cancer in India

A recent comprehensive study conducted in India has revealed a remarkable 94.5% overall survival rate for children who have successfully completed treatment for cancer. The findings, released on the eve of International Childhood Cancer Day, highlight the importance of addressing not just survival but also the long-term challenges faced by these young patients.

Study Overview and Key Findings

The Indian Childhood Cancer Survivorship study, spearheaded by the Indian Paediatric Haematology Oncology Group, tracked over 5,400 children across major cities including Delhi, Mumbai, Chennai, Kolkata, and Bengaluru. It was initiated in 2016 and has published findings in The Lancet Regional Health – Southeast Asia. The data spans from 2016 to 2024, offering a robust overview of the survival landscape for childhood cancer in India.

The preliminary results indicate a high success rate, with an event-free survival rate of 89.9%. Notably, two years post-treatment, the survival rate increases to 98.2%. As per follow-up data reviewed in December 2024, 92% of the children were alive and in remission, showcasing the efficacy of current treatment protocols.

Treatment Insights and Medical Interventions

Among the cancers diagnosed, leukemia accounted for 41%, making it the most common type within this cohort. Other cancers included Hodgkin lymphoma, bone tumors, and retinoblastoma. Treatment modalities primarily involved chemotherapy, with approximately 25% of patients receiving radiotherapy. Moreover, around one-third underwent surgical interventions, and over half required blood transfusions, underscoring the complexity of care required for these young patients.

Despite these encouraging survival statistics, Dr. Rachna Seth, who leads the oncology division at AIIMS, New Delhi, emphasized the need to address the long-term effects experienced by survivors. She pointed out that many may face challenges such as fertility issues, cardiac dysfunction, cognitive difficulties, and the risk of secondary cancers. “It is crucial that these late effects are systematically documented,” Dr. Seth stated, highlighting a significant gap in understanding the post-treatment landscape in India.

The study has expanded its reach, now including data from 35 to 36 medical centers, which enhances the reliability of the findings. The median follow-up period from diagnosis is approximately 3.9 years. Notably, the study reported a 5.7% relapse rate, while 4.9% of children did not survive through the follow-up phase, reflecting the ongoing challenges in childhood cancer treatment.

This comprehensive analysis marks a critical advancement in understanding the long-term outcomes for children treated for cancer in India. By focusing on survivorship, the research aims to foster improved healthcare strategies and support systems for young patients and their families, paving the way for a more informed approach to childhood cancer care in the region.